InsiderTradesSIGMA

PicksTOP Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FRUSDEGBCHCAITESNLBENOSEFIDKAUATIEBRINJP+ 8 markets

Recommendations
Companies
Insiders
Performance
Backtest
Compare

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

Theme: dark (range regime detected on CAC40 90d · as of 2026-05-22)

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

All systems operational

InsidersTradesSigma

Abhishek Maini — personal trades · 21 reports

← Executives ★ Sign in to follow

AM

Abhishek Maini

ININ·SEBI (PIT + SAST)

Dr. Lal Path Labs Ltd.

Cumul. flow

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Discover the complete record of transactions filed by Abhishek Maini. Director active across 1 companies, notably Dr. Lal Path Labs Ltd.. In total, 21 reports have been logged. The latest transaction was disclosed on 21 August 2025 — Purchase. Regulator: SEBI (PIT + SAST). The full history is openly available.

Declarations21 total

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€4,756250 shares@ €19.0245

Equity Shares

SEBI:ad481f450d1b4007729fc715e2009f2753c7581c·21 Aug 2025

Ideal exit: 18 May 2026 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€8,194250 shares@ €32.7767

Equity Shares

SEBI:86fea8d19cbdb1da4c1f0c996a2922f1b7fb8fc5·28 Aug 2025

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€18186 shares@ €0.0979

Equity Shares

SEBI:748d272a037b594192bc84068c8a879e2ece16c0·8 Aug 2025

Ideal exit: 5 May 2026 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€5,963186 shares@ €32.0582

Equity Shares

SEBI:4dcb1ea40d21fe3eec1826c0912dae4de34e407e·13 Aug 2025

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€19,224562 shares@ €34.2063

Equity Shares

SEBI:9b73459a6bfb0d3c6629f36a34bd203e44aa7968·9 Dec 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€63562 shares@ €0.1129

Equity Shares

SEBI:3271c2ea7d1f5fb045a2e4bf42b5e08bc6d63f59·27 Nov 2024

Ideal exit: 24 Aug 2025 (T+270)

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€5,155250 shares@ €20.6207

Equity Shares

SEBI:34c429ed5199784e354c236011ecc4cd44b18f67·24 Sept 2024

Ideal exit: 21 Jun 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€8,992250 shares@ €35.9696

Equity Shares

SEBI:cf79a23e3ebbe410217f6e823a4c4e5c31eb0287·25 Sept 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€6,879188 shares@ €36.591

Equity Shares

SEBI:83fc8409183391aca19b43409b9e2ec655c4947b·10 Sept 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€20188 shares@ €0.1074

Equity Shares

SEBI:d14e3bffcc852264e7867a0dae90ec21cd87ffdb·4 Sept 2024

Ideal exit: 1 Jun 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€8,905250 shares@ €35.6203

Equity Shares

SEBI:baa8f2b938fa60963b2aed1ad7db503380da0215·27 Aug 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€5,148250 shares@ €20.5917

Equity Shares

SEBI:7157b50546a28acc27c2cb7b7be6403df1ccb5bc·26 Aug 2024

Ideal exit: 23 May 2025 (T+270)

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€20188 shares@ €0.1071

Equity Shares

SEBI:77dceb3b5eaf589037f5de88ecc6040711c984cc·20 Aug 2024

Ideal exit: 17 May 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€6,615188 shares@ €35.1838

Equity Shares

SEBI:225b1240d2cf6b7f8d0f8e212463aa8b41c48a04·21 Aug 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€20188 shares@ €0.1083

Equity Shares

SEBI:8c0170dc2a4ef59141348c2aef25fcec476cd362·13 Aug 2024

Ideal exit: 10 May 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€6,569188 shares@ €34.9401

Equity Shares

SEBI:42fa26432f08f2624ad04451d2e7c396db4a25b5·14 Aug 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€58525 shares@ €0.1101

Equity Shares

SEBI:0794cf5ae1ad7e84c499812ed9ad87995b95de28·16 May 2024

Ideal exit: 10 Feb 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€13,062500 shares@ €26.124

Equity Shares

SEBI:22f09b7b6d8f81124261f855be89971691d8b633·14 Sept 2023

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€65590 shares@ €0.1098

Equity Shares

SEBI:c969c3df4f4661c0d10e17da9e35700adf2f5213·9 Aug 2023

Ideal exit: 5 May 2024 (T+270)

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€35308 shares@ €0.1149

Equity Shares

SEBI:4ecb03ac4062d403b517cce16b13885c98c8ace6·14 Oct 2021

Ideal exit: 11 Jul 2022 (T+270)

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€35300 shares@ €0.1152

Equity Shares

SEBI:15bb87074625b69e6e3c5babf77330c6efb8a96b·28 Sept 2021

Ideal exit: 25 Jun 2022 (T+270)

21 of 21 declarations